Literature DB >> 28991674

Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose.

Nayara Felicidade Tomaz Braz1, Natalia Pessoa Rocha1, Érica Leandro Marciano Vieira1, Rodrigo Santiago Gomez2, Adriana Maria Kakehasi3, Antonio Lucio Teixeira4.   

Abstract

This study aimed to evaluate changes in body composition, i.e. overweight, obesity, fat accumulation and low lean body mass and plasma levels of adipokines in patients with MG. The study enrolled 80 patients with MG, and 62 controls. Body fat mass and body lean mass was analyzed by dual-energy X-ray absorptiometry technique (DXA). Plasma levels of leptin were analyzed by Luminex® and adiponectin and resistin were analyzed by ELISA. The mean age of patients with MG was 41.9years, with 13.5years of length of illness, and mean cumulative dose of glucocorticoids 38,123mg. Our results showed that the frequency of obesity is higher in MG patients than in controls, and patients with MG presented higher body fat mass, android body adiposity and total body fat than controls. MG patients presented lower levels of resistin and higher levels of leptin in comparison with controls. There were no differences in the plasma levels of adiponectin. Higher total body fat and lower body lean mass were associated with increased severity of MG symptoms. This result points to the relevance of estimation of body composition in planning long-term care of MG patients.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adipokines; Body composition; Dual-energy X-ray absorptiometry; Myasthenia gravis; Obesity

Mesh:

Substances:

Year:  2017        PMID: 28991674     DOI: 10.1016/j.jns.2017.08.3250

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Minimal manifestation status and prednisone withdrawal in the MGTX trial.

Authors:  Ikjae Lee; Hui-Chien Kuo; Inmaculada B Aban; Gary R Cutter; Tarrant McPherson; Henry J Kaminski; Jon Sussman; Philipp Ströbel; Joel Oger; Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Marcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Jan J G Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Greg Minisman; Joshua R Sonett; Gil I Wolfe
Journal:  Neurology       Date:  2020-07-01       Impact factor: 9.910

Review 2.  A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature.

Authors:  Maria Elena Farrugia; John A Goodfellow
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

3.  Distribution of serum adiponectin isoforms in pediatric patients with steroid-sensitive nephrotic syndrome.

Authors:  Tetsuro Tamai; Kaori Kamijo; Yoshifusa Abe; Satoshi Hibino; Shunsuke Sakurai; Shuichiro Watanabe; Yoshitaka Watanabe; Satomi Nimura; Atsutoshi Shiratori; Takaaki Takayanagi; Tsuneki Watanabe; Yuya Nakano; Hirokazu Ikeda; Kazushige Dobashi; Yasuko Nakano; Katsumi Mizuno; Kazuo Itabashi
Journal:  Clin Exp Nephrol       Date:  2021-06-01       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.